MedPath

Qurient Co., Ltd.

Qurient Co., Ltd. logo
🇰🇷South Korea
Ownership
Public
Established
2008-07-02
Employees
32
Market Cap
-
Website
http://www.qurient.com

Clinical Trials

9

Active:1
Completed:5

Trial Phases

2 Phases

Phase 1:5
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (55.6%)
Phase 2
4 (44.4%)

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Esophageal Cancer
Gastric Cancer
Hepatocellular Cancer
Cervical Cancer
Interventions
Biological: Pembrolizumab
First Posted Date
2022-06-30
Last Posted Date
2024-03-12
Lead Sponsor
Qurient Co., Ltd.
Target Recruit Count
120
Registration Number
NCT05438420
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

Norton Cancer Institute, Louisville, Kentucky, United States

🇰🇷

CHA Bundang Medical Center, Seongnam-si, Korea, Republic of

and more 4 locations

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Metastatic Cancer
Advanced Cancer
Interventions
First Posted Date
2022-05-27
Last Posted Date
2024-03-12
Lead Sponsor
Qurient Co., Ltd.
Target Recruit Count
130
Registration Number
NCT05394103
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 4 locations

A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients

Phase 2
Terminated
Conditions
COVID-19 Virus Infection
Interventions
Drug: COVID-19 Standard of care
First Posted Date
2021-04-19
Last Posted Date
2022-03-02
Lead Sponsor
Qurient Co., Ltd.
Target Recruit Count
1
Registration Number
NCT04847583
Locations
🇿🇦

Chris Hani Baragwanath Academic Hospital, Soweto, Gauteng, South Africa

🇿🇦

KwaPhila Health Solutions, Durban, Kwa-Zula Natal, South Africa

🇿🇦

TASK Eden, George, Western Cape, South Africa

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor

Phase 1
Active, not recruiting
Conditions
Solid Tumor
Advanced Cancer
Metastatic Cancer
Interventions
First Posted Date
2020-12-01
Last Posted Date
2024-11-27
Lead Sponsor
Qurient Co., Ltd.
Target Recruit Count
78
Registration Number
NCT04648254
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 1 locations

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Vehicle
Drug: Q301 Cream
First Posted Date
2018-06-27
Last Posted Date
2020-04-24
Lead Sponsor
Qurient Co., Ltd.
Target Recruit Count
258
Registration Number
NCT03571620
Locations
🇺🇸

Wake Forest School of Medicine Department of Dermatology, Winston-Salem, North Carolina, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.